GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Company profile
Ticker
GHRS
Exchange
Website
CEO
Dr. Velichka Valcheva M.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Blue Water Biotech, Inc., Blue Water Vaccines Inc.
SEC CIK
GHRS stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
20 Sep 24
6-K
Current report (foreign)
16 Sep 24
6-K
Current report (foreign)
9 Sep 24
6-K
Current report (foreign)
3 Sep 24
6-K
GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
3 Sep 24
6-K
Unaudited condensed consolidated interim statement of comprehensive income
3 Sep 24
6-K
Current report (foreign)
28 Jun 24
6-K
Current report (foreign)
24 Jun 24
6-K
Notice of Annual General Meeting to be held on 27 June 2024
15 May 24
6-K
Unaudited condensed consolidated interim statement of comprehensive income
3 May 24
Latest ownership filings
SC 13G
Lynx1 Capital Management LP
16 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
30 Mar 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 23
SC 13G/A
Schonharting Florian
10 Feb 23
Financial summary
| Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
Institutional ownership, Q2 2024
83.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 2 |
| Closed positions | 5 |
| Increased positions | 8 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 354.54 bn |
| Total shares | 43.22 mm |
| Total puts | 1.90 k |
| Total calls | 63.10 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| BVF | 10.40 mm | $121.27 bn |
| Biotechnology Value Fund L P | 9.28 mm | $0.00 |
| Ra Capital Management | 6.60 mm | $76.98 bn |
| Lynx1 Capital Management | 3.97 mm | $46.25 bn |
| Venrock Healthcare Capital Partners II | 3.52 mm | $0.00 |
| RTW Investments | 3.33 mm | $38.79 bn |
| FMR | 2.97 mm | $34.59 bn |
| Verition Fund Management | 1.14 mm | $13.30 bn |
| Cormorant Asset Management | 593.04 k | $6.91 bn |
| 5AM Venture Management | 572.67 k | $6.68 bn |
News
HC Wainwright & Co. Reiterates Buy on GH Research, Maintains $40 Price Target
5 Sep 24
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
5 Sep 24
JMP Securities Reiterates Market Outperform on GH Research, Maintains $39 Price Target
4 Sep 24
GH Research Appoints Dr. Velichka 'Villy' Valcheva As New Chief Executive Officer
3 Sep 24